243 related articles for article (PubMed ID: 33050272)
1. Daratumumab Monotherapy in Severe Patients with AL Amyloidosis and Biopsy-Proven Renal Involvement: A Real Life Experience.
Roccatello D; Fenoglio R; Naretto C; Baldovino S; Sciascia S; Ferro M; Rossi D
J Clin Med; 2020 Oct; 9(10):. PubMed ID: 33050272
[TBL] [Abstract][Full Text] [Related]
2. Clinical Pharmacokinetics and Pharmacodynamics of Daratumumab.
Kim K; Phelps MA
Clin Pharmacokinet; 2023 Jun; 62(6):789-806. PubMed ID: 37129750
[TBL] [Abstract][Full Text] [Related]
3. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
[TBL] [Abstract][Full Text] [Related]
5. Daratumumab plus CyBorD for patients with newly diagnosed light chain (AL) amyloidosis.
Theodorakakou F; Dimopoulos MA; Kastritis E
Ther Adv Hematol; 2021; 12():20406207211058334. PubMed ID: 34840708
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab in AL Amyloidosis: A Real-Life Experience of the "RTM" (Regional Tuscan Myeloma Network).
Sammartano V; Antonioli E; Buda G; Ciofini S; Candi V; Pengue L; Del Giudice ML; Attucci I; Bacchiarri F; Occhini U; Pirrotta MT; Perfetto F; Bocchia M; Gozzetti A
J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330483
[TBL] [Abstract][Full Text] [Related]
7. Successful Treatment of Systemic Light Chain Amyloidosis with Liver Involvement using Low-Frequency Daratumumab: A Case Report.
Meng X; He J; Cheng F; Yan H; Zhu C; Guo X; Li Y; Cai Z; He D
Am J Case Rep; 2024 Jan; 25():e942534. PubMed ID: 38229422
[TBL] [Abstract][Full Text] [Related]
8. Outcome of patients with severe AL amyloidosis and biopsy-proven renal involvement ineligible for bone marrow transplantation.
Fenoglio R; Baldovino S; Ferro M; Sciascia S; Rabajoli G; Quattrocchio G; Beltrame G; Naretto C; Rossi D; Alpa M; Barreca A; Papotti MG; Roccatello D
J Nephrol; 2021 Feb; 34(1):231-240. PubMed ID: 32472525
[TBL] [Abstract][Full Text] [Related]
9. Daratumumab for relapsed or refractory AL amyloidosis with high plasma cell burden.
Schwotzer R; Manz MG; Pederiva S; Waibel C; Caspar C; Lerch E; Flammer AJ; Brouwers S; Seeger H; Heimgartner R; Fehr T; Rossi D; Bianchi E; Stüssi G; Ghilardi G; Gerber B
Hematol Oncol; 2019 Dec; 37(5):595-600. PubMed ID: 31486522
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion.
Ghose J; Viola D; Terrazas C; Caserta E; Troadec E; Khalife J; Gunes EG; Sanchez J; McDonald T; Marcucci G; Kaur B; Rosenzweig M; Keats J; Rosen S; Krishnan A; Satoskar AR; Hofmeister CC; Pichiorri F
Oncoimmunology; 2018; 7(10):e1486948. PubMed ID: 30288349
[TBL] [Abstract][Full Text] [Related]
11. First report of outcomes in patients with stage IIIb AL amyloidosis treated with Dara-VCD front-line therapy.
Chakraborty R; Rosenbaum C; Kaur G; Bhutani D; Radhakrishnan J; Mapara MY; Maurer M; Lentzsch S
Br J Haematol; 2023 Jun; 201(5):913-916. PubMed ID: 36896578
[TBL] [Abstract][Full Text] [Related]
12. Time to Redefine Risk-Stratification and Response Criteria in Immunoglobulin Light Chain Amyloidosis?
Jain A; Ramasamy K
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e769-e776. PubMed ID: 32653456
[TBL] [Abstract][Full Text] [Related]
13. Investigation into the interference of the monoclonal antibody daratumumab on the free light chain assay.
Rosenberg AS; Bainbridge S; Pahwa R; Jialal I
Clin Biochem; 2016 Oct; 49(15):1202-1204. PubMed ID: 27475249
[TBL] [Abstract][Full Text] [Related]
14. Evolving Role of Daratumumab: From Backbencher to Frontline Agent.
Jain A; Ramasamy K
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):572-587. PubMed ID: 32331971
[TBL] [Abstract][Full Text] [Related]
15. Complete Depletion of Daratumumab Interference in Serum Samples from Plasma Cell Myeloma Patients Improves the Detection of Endogenous M-Proteins in a Preliminary Study.
Vakili H; Koorse Germans S; Dong X; Kansagra A; Patel H; Muthukumar A; Hashim IA
Diagnostics (Basel); 2020 Apr; 10(4):. PubMed ID: 32295157
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy.
Dima D; Hughes M; Orland M; Ullah F; Goel U; Anwer F; Raza S; Mazzoni S; Bhutani D; Williams L; Lentzsch S; Samaras C; Valent J; Chakraborty R; Khouri J
Amyloid; 2024 Jul; ():1-7. PubMed ID: 38956891
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Treatment of light-chain amyloidosis with daratumumab monotherapy in two patients.
Gran C; Gahrton G; Alici E; Nahi H
Eur J Haematol; 2018 Apr; 100(4):386-388. PubMed ID: 29226427
[TBL] [Abstract][Full Text] [Related]
18. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
[TBL] [Abstract][Full Text] [Related]
19. First-line daratumumab shows high efficacy and tolerability even in advanced AL amyloidosis: the real-world experience.
Jeryczynski G; Antlanger M; Duca F; Binder-Rodriguez C; Reiter T; Simonitsch-Klupp I; Bonderman D; Kain R; Krauth MT; Agis H
ESMO Open; 2021 Apr; 6(2):100065. PubMed ID: 33667762
[TBL] [Abstract][Full Text] [Related]
20. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis.
Kaufman GP; Schrier SL; Lafayette RA; Arai S; Witteles RM; Liedtke M
Blood; 2017 Aug; 130(7):900-902. PubMed ID: 28615223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
